Insiders have been buying Medibank and this ASX share

Insiders have been buying Medibank Private Ltd (ASX:MPL) and this ASX share in May. Here's what you need to know…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I like to keep a close eye on which shares have experienced meaningful insider buying.

This is because insider buying is often regarded as a bullish indicator, as few people know a company and its intrinsic value better than its own directors.

A number of shares have reported meaningful insider buying this week. Here are a couple which have caught my eye:

Adairs Ltd (ASX: ADH)

According to a change of director's interest notice, one of this homewares retailer's independent non-executive directors has been buying shares this month. The notice reveals that Independent Non-Executive Director Kiera Grant picked up 106,000 shares through an on-market trade on 15 May. The director paid a total of $150,339.80 for the shares, which equates to an average of $1.42 per share. This purchase lifted Grant's holding to a total of 142,572 shares.

Earlier this month, Adairs revealed that its online sales grew a massive 221% while its stores were closed because of the pandemic. Judging by the investment, it appears as though this director is confident its strong form can continue.

Medibank Private Ltd (ASX: MPL)

A change of director's interest notice reveals that one of this private health insurer's independent non-executive directors has made a sizeable purchase of shares in May. According to the notice, Tracey Batten picked up 15,715 shares through an on-market trade on 14 May. Batten paid an average of $2.85 per share, which is slightly higher than today's price. This works out to be a total consideration of just under $45,000 and lifts the director's holding to a total of 50,000 shares.

This purchase price represents a 22.5% discount to Medibank's 52-week high. Which appears to be a level this director thinks is good value. One broker that might agree is Credit Suisse. Earlier this month it put an outperform rating and $3.00 price target on the company's shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »